Heparin Binds Plasma Proteins: Angiomax ® (Bivalirudin) Binds Specifically to Thrombin Heparin (long strand) binds to other plasma proteins (colored molecules)

Slides:

Advertisements

Similar presentations

Carlo Briguori, MD, FACC, FSCAI Clinica Mediterranea, Naples, Italy

Advertisements

Heparin Resistance “Heparin resistance is a term used to describe the situation when patients require unusually high doses of heparin to achieve a therapeutic.

Thrombus Susceptibility and the Vulnerable Plaque Relationship Between Inflammation and Thrombosis.

Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.

Anti-platelet drugs Dr. Ishfaq Bukhari Dec

Antiplatelet Drugs (Anti-thrombotics)

Dr. Ishfaq Bukhari.  In healthy vasculature, circulating platelets are maintained in an inactive state by nitric oxide (NO) and prostacyclinre (PGI2)leased.

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.

Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease Dominick J. Angiolillo,

ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.

Measurement of Clopidogrel Resistance by ADP-Inhibition Does Not Reflect the Benefit of Clopidogrel on Overall Thrombotic Status Dr Diana A Gorog Consultant.

Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Clopidogrel 75 mg per day orally should be added to aspirin in patients with STEMI regardless of whether they undergo reperfusion.

1 Replace Heparin and Improve Outcomes New Antithrombotic Strategies in ACS Patients Undergoing PCI ANG-PSL-XXX-XXX.

Applications of bivalirudin in interventional cardiology

ANTIPLATELET DRUGS.

ASPIRIN ↓ Cox inhibition ↓ (PROSTACYCLIN) PGI 2 & TXA 2 (THROMBOXANE) LOW DOSE ASPIRIN.

“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.

INCITE Study Co-PI: Frederick Welt, M.D. Co-PI: Daniel I. Simon, M.D. Brigham and Women’s Hospital West Roxbury VA Medical Center Harvard Medical School.

Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.

ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.

ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.

Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.

TRIP: Thrombotic Risk Progression TRIP: Thrombotic Risk Progression Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of.

Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin Advancing Anticoagulation in ACS.

Anticoagulation to the max A Michael Lincoff MD Cardiologist Division of Cardiology Cleveland Clinic Cleveland, OH.

Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.

Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.

Newer Antiplatelet Agents Epifibatide Tirofiban Etc. Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

Prof. Abdulrahman Almotrefi

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Www. Clinical trial results.org Heparin Increases Platelet Activation Heparin (yellow strands) makes platelets more reactive to activation by other agonists.

The Opus Trial. Antithrombotic Therapy Stable Angina Unstable Angina ST Elevation MI Non-Q wave MI Thrombolysis Non-ST Elevation MI Q wave MI.

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.

Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann.

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.

Drugs Used in Coagulation Disorders

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Platelet Biology and Response to Antiplatelet Therapy.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacologic plaque passivation for the reduction.

II. Antiplatelet Drugs.

Bivalirudin Drugbank ID : DB00006

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.

Antithrombotic drugs Fibrinolytics

Anesthes. 1997;87(3): Figure Legend:

HIT: The Consequences of Heparin’s Nonspecific Binding to Platelet Factor 4 Heparin is neutralized by platelet factor 4, (PF4), which is present in high.

Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis Andrew.

Arterioscler Thromb Vasc Biol

Anti-Coagulants Physical Process of Clotting

Anti-Thrombotic Review

Indirect vs Direct Thrombin Inhibition

Angiomax® (bivalirudin) Inhibits Clot-Bound Thrombin

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Binding properties of P2Y12-receptor inhibitors

Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Mechanism of thrombus formation during ST-segment

Bivalirudin is Cleaved by Thrombin so that there is a Rapid Return to Hemostasis and a Safety Advantage Heparin’s effects on platelets and its reappearance.

Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis Andrew.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Becker RC, et al. Lancet 2009;373:919-28

Antithrombotic and prothrombotic molecules Content Points:

Heparin Binds Plasma Proteins; Angiomax® (bivalirudin) Binds Specifically to Thrombin Heparin (long strand) binds to other plasma proteins (colored molecules)

Antithrombin Therapy in the Management of ACS

TEG platelet map tracing.

C-2. Clinical trial updates: Direct thrombin inhibitors

The identification and management of heparin-induced thrombocytopenia in the vascular patient Glenn M. LaMuraglia, MD, Rabih Houbballah, MD, Michael.

Section B: Science update

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Heparin-induced thrombocytopenia

Presentation transcript:

Heparin Binds Plasma Proteins: Angiomax ® (Bivalirudin) Binds Specifically to Thrombin Heparin (long strand) binds to other plasma proteins (colored molecules) and platelets, reducing heparin’s availability to bind to AT. Heparin-binding proteins are elevated in acute coronary syndrome (ACS). Angiomax (bright blue) binds only to thrombin (orange). Angiomax is not neutralized by other plasma proteins or platelets; it remains fully active near thrombus. Hirsh J et al. Chest. 2001;119(1 suppl):64S-94S. Weitz JI et al. Thromb Res. 2002;106:V275-V284. Wittkowsky AK. Pharmacother. 2002;22(6 Pt 2):97S-104S.

Consequences of Nonspecific Binding Heparin is neutralized by platelet factor 4, (PF4), which is present in high concentrations near vascular injury. Thrombin continues activating platelets. PF4/heparin complex antibodies activate platelets, causing thrombocytopenia as well as heparin-induced thrombocytopenia thrombosis syndrome (HIT/TS). Angiomax ® (bivalirudin) does not bind to PF4, and remains fully active. There is no risk of HIT/TS or other thrombotic events associated with PF4/heparin antibodies. Weitz JI et al. Thromb Res. 2002;106:V275-V284. Williams RT et al. Circulation. 2003;107:

Heparin Increases Platelet Activation Heparin makes platelets more reactive to activation by other agonists, such as adenosine diphosphate (ADP). Heparin binds to the platelet GP IIb/IIIa receptor. Given the various ways heparin increases platelet activation, its use may actually increase the need for antiplatelet agents. Becker R et al. J Invasive Cardiol. 2003;(suppl):1-15. Sobel M et al. J Vasc Surg. 2001;33: Xiao Z et al. Circulation. 1998;97:

Heparin Has a Direct Effect on Platelets Heparin increases platelet activation in unstable angina patients Reproduced with permission of Xiao Z et al. Circulation. 1998;97:253. P<0.001 Maximum Aggregation (%) ADP ( µM) TRAP (0.625 µM) Pre-heparin Heparin TRAP=thrombin receptor agonist peptide.

34% 38% 34% 42% UFHAngiomax Percentage Angiomax ® (Bivalirudin) Significantly Decreases Platelet Reactivity Platelet reactivity in response to 1 μM ADP Fibrin binding P-selectin expression P< P=0.01 Aggarwal A et al. J Thromb Thrombolysis. 2002;13: